Visterra was a pre-clinical stage private biopharmaceutical company based in Waltham, United States. The company specialized in the development of innovative antibody-based therapies for kidney and other hard-to-treat diseases. The company’s Hierotope platform was designed to identify and target specific regions on antigens that are critical to their structure and function. In 2018, Visterra was acquired by Otsuka for $430M USD.
Kidney diseases
CTI LSF II
Syndicate
Observer
January 28, 2016
Visterra acquired by Otsuka for $430M USD
Series C
Visterra had a proprietary technology platform, Hierotope, to design precision biologics that specifically bind to and modulate key disease targets
